

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Pipeline Review, H1 2018

<https://marketpublishers.com/r/T29F5B181C5EN.html>

Date: May 2018

Pages: 132

Price: US\$ 3,500.00 (Single User License)

ID: T29F5B181C5EN

Abstracts

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Pipeline Review, H1 2018

SUMMARY

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Tyrosine-protein kinase receptor UFO is an enzyme encoded by the AXL gene. It plays a role in various processes such as endothelial cell survival during acidification by preventing apoptosis, optimal cytokine signaling during human natural killer cell development, hepatic regeneration, gonadotropin-releasing hormone neuron survival and migration, platelet activation, or regulation of thrombotic responses. It plays also an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response.

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) pipeline Target constitutes close to 27 molecules. Out of which approximately 26 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 4, 5, 1, 12 and 2 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular and Respiratory which include indications Non-Small Cell Lung Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Solid Tumor, Breast Cancer, Ovarian Cancer, Refractory Acute Myeloid Leukemia, Pancreatic Cancer, Relapsed Acute

Myeloid Leukemia, Bladder Cancer, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Gastric Cancer, Hepatocellular Carcinoma, Lung Adenocarcinoma, Melanoma, Metastatic Colorectal Cancer, Metastatic Renal Cell Carcinoma, Renal Cell Carcinoma, Soft Tissue Sarcoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Bile Duct Cancer (Cholangiocarcinoma), Bone Metastasis, Carcinoid Tumor, Colorectal Cancer, Endometrial Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Ewing Sarcoma, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor (GIST), Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Idiopathic Pulmonary Fibrosis, Kidney Cancer (Renal Cell Cancer), Liposarcoma, Liver Cancer, Lung Cancer, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Brain Tumor, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Prostate Cancer, Myelodysplastic Syndrome, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), Neuroendocrine Tumors, Non-Rhabdomyosarcoma, Ocular Melanoma, Osteosarcoma, Pancreatic Ductal Adenocarcinoma, Peritoneal Cancer, Pheochromocytoma, Recurrent Glioblastoma Multiforme (GBM), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rhabdomyosarcoma, Thrombosis, Thyroid Cancer, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Ureter Cancer, Urethral Cancer, Uterine Cancer and Wilms' Tumor (Nephroblastoma).

The latest report Tyrosine Protein Kinase Receptor UFO - Pipeline Review, H1 2018, outlays comprehensive information on the Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1)

The report reviews Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) -
Overview

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) -
Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) -
Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) -
Companies Involved in Therapeutics Development

ADC Therapeutics SA

Astellas Pharma Inc

BerGenBio ASA

Betta Pharmaceuticals Co Ltd

Celldex Therapeutics Inc

Daiichi Sankyo Co Ltd

Exelixis Inc

F1 Oncology Inc

Ignity Inc

Incyte Corp

Les Laboratoires Servier SAS

Mirati Therapeutics Inc

Ono Pharmaceutical Co Ltd

Oribase Pharma

Qurient Co Ltd

Rigel Pharmaceuticals Inc

SignalChem Lifesciences Corp

Takeda Pharmaceutical Co Ltd

Tolero Pharmaceuticals Inc

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Drug Profiles

ADCT-601 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibodies to Inhibit AXL, MERTK and TYRO3 for Oncology, Inflammation, Autoimmune Diseases and Infectious Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bemcentinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGB-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGB-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGB-149 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGB-601 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BPI-9016 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cabozantinib s-malate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCT-30138 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CT-053 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CT-413 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DS-1205 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Inhibit Axl Tyrosine kinase for Non-Small Cell Lung Cancer and Thrombosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gilteritinib fumarate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HOPE-777 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INCB-81776 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONO-7475 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ORY-012 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Q-701 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-916562 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RXDX-106 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-49076 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sitravatinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SLC-0211 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit AXL for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TP-0903 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) -
Dormant Products

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) -
Discontinued Products

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) -

Product Development Milestones

Featured News & Press Releases

Apr 26, 2018: Cabozantinib to Be Featured in 15 Presentations at ASCO 2018 Annual Meeting

Apr 23, 2018: Astellas Submits New Drug Applications for Approval of Gilteritinib for the Treatment of FLT3mut+ Relapsed or Refractory Acute Myeloid Leukemia

Apr 18, 2018: BerGenBio: Promising data highlighting selective AXL inhibitor bemcentinib's potential to improve efficacy of checkpoint inhibitors presented at AACR

Apr 13, 2018: Promising pre-clinical data supporting BerGenBios pipeline to be published and presented at upcoming leading conferences

Apr 11, 2018: ADC Therapeutics to Present New Investigational Antibody-Drug Conjugate ADCT-601 at the American Association for Cancer Research (AACR) Annual Meeting

Apr 10, 2018: BerGenBio Completes Recruitment Into First Stage of Phase II NSCLC Trial With Selective AXL Inhibitor Bemcentinib Combined With KEYTRUDA

Mar 28, 2018: Ipsen Announces EMA Validation of Filing of a New Application for Additional Indication for Cabometyx, for patients with previously treated advanced Hepatocellular Carcinoma (HCC)

Mar 23, 2018: Exelixis Partner Ipsen Announces Positive CHMP Opinion for CABOMETYX (cabozantinib) for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma

Mar 22, 2018: BerGenBio to present overview of phase II clinical trial portfolio combining bemcentinib with KEYTRUDA at 3rd Annual Immuno-Oncology Summit Europe

Mar 22, 2018: Astellas Receives Orphan Drug Designation from the Japanese MHLW for Gilteritinib

Mar 15, 2018: Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX (Cabozantinib) for Previously Treated Advanced Hepatocellular Carcinoma

Mar 15, 2018: BerGenBio: Promising data highlighting bemcentinib's potential to improve efficacy of checkpoint inhibitors to be presented at AACR Annual Meeting

Feb 19, 2018: BerGenBio Completes Recruitment Into First Stage of Phase II Breast Cancer Trial With Selective AXL Inhibitor Bemcentinib Combined With KEYTRUDA

Feb 15, 2018: Ipsen's rare medullary thyroid cancer treatment Cometriq (cabozantinib), gets nod from NICE

Feb 13, 2018: Cabozantinib shows significant activity in the first line for differentiated thyroid cancer

Appendix

Methodology

[Coverage](#)
[Secondary Research](#)
[Primary Research](#)
[Expert Panel Validation](#)
[Contact Us](#)
[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.2), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.3), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd.1)
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Products under Development by Companies, H1 2018 (Contd.2), H1 2018
Products under Development by Companies, H1 2018 (Contd.3), H1 2018
Products under Development by Companies, H1 2018 (Contd.4), H1 2018
Products under Development by Companies, H1 2018 (Contd.5), H1 2018
Products under Development by Companies, H1 2018 (Contd.6), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by ADC Therapeutics SA, H1 2018
Pipeline by Astellas Pharma Inc, H1 2018
Pipeline by BerGenBio ASA, H1 2018
Pipeline by Betta Pharmaceuticals Co Ltd, H1 2018
Pipeline by Celldex Therapeutics Inc, H1 2018
Pipeline by Daiichi Sankyo Co Ltd, H1 2018
Pipeline by Exelixis Inc, H1 2018
Pipeline by F1 Oncology Inc, H1 2018
Pipeline by Ignyta Inc, H1 2018
Pipeline by Incyte Corp, H1 2018
Pipeline by Les Laboratoires Servier SAS, H1 2018
Pipeline by Mirati Therapeutics Inc, H1 2018
Pipeline by Ono Pharmaceutical Co Ltd, H1 2018
Pipeline by Oribase Pharma, H1 2018
Pipeline by Qurient Co Ltd, H1 2018

Pipeline by Rigel Pharmaceuticals Inc, H1 2018
Pipeline by SignalChem Lifesciences Corp, H1 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
Pipeline by Tolero Pharmaceuticals Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Dormant Products, H1 2018 (Contd.2), H1 2018
Discontinued Products, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

ADC Therapeutics SA

Astellas Pharma Inc

BerGenBio ASA

Betta Pharmaceuticals Co Ltd

Celldex Therapeutics Inc

Daiichi Sankyo Co Ltd

Exelixis Inc

F1 Oncology Inc

Ignity Inc

Incyte Corp

Les Laboratoires Servier SAS

Mirati Therapeutics Inc

Ono Pharmaceutical Co Ltd

Oribase Pharma

Qurient Co Ltd

Rigel Pharmaceuticals Inc

SignalChem Lifesciences Corp

Takeda Pharmaceutical Co Ltd

Tolero Pharmaceuticals Inc

I would like to order

Product name: Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/T29F5B181C5EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T29F5B181C5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

